Omnicell, Inc. to Post Q3 2024 Earnings of $0.17 Per Share, Zacks Research Forecasts (NASDAQ:OMCL)

Omnicell, Inc. (NASDAQ:OMCL) – Equities researchers at Zacks Research lifted their Q3 2024 earnings per share estimates for shares of Omnicell in a research report issued on Tuesday, September 10th. Zacks Research analyst U. Biswas now expects that the company will post earnings per share of $0.17 for the quarter, up from their previous estimate of $0.16. The consensus estimate for Omnicell’s current full-year earnings is $0.64 per share. Zacks Research also issued estimates for Omnicell’s Q4 2024 earnings at $0.17 EPS, FY2024 earnings at $0.55 EPS, Q1 2025 earnings at $0.13 EPS, Q3 2025 earnings at $0.11 EPS, Q4 2025 earnings at $0.12 EPS and FY2025 earnings at $0.49 EPS.

A number of other research firms have also recently issued reports on OMCL. Bank of America raised their target price on Omnicell from $34.00 to $44.00 and gave the company a “buy” rating in a research note on Friday, August 2nd. Benchmark reiterated a “buy” rating and issued a $38.00 price objective on shares of Omnicell in a research report on Monday, July 15th. Wells Fargo & Company upped their target price on shares of Omnicell from $26.00 to $30.00 and gave the stock an “equal weight” rating in a research report on Friday, August 2nd. Barclays raised Omnicell from an “underweight” rating to an “equal weight” rating and lifted their price target for the company from $26.00 to $39.00 in a report on Friday, August 2nd. Finally, JPMorgan Chase & Co. boosted their price objective on Omnicell from $26.00 to $37.00 and gave the stock a “neutral” rating in a research report on Friday, August 23rd. Four research analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $37.83.

Omnicell Stock Up 0.8 %

Shares of Omnicell stock opened at $43.16 on Thursday. The stock has a market capitalization of $1.98 billion, a price-to-earnings ratio of -93.83, a PEG ratio of 47.48 and a beta of 0.83. Omnicell has a twelve month low of $25.12 and a twelve month high of $56.06. The company has a current ratio of 2.45, a quick ratio of 2.22 and a debt-to-equity ratio of 0.47. The business’s 50 day simple moving average is $37.42 and its 200-day simple moving average is $31.63.

Omnicell (NASDAQ:OMCL) last released its earnings results on Thursday, August 1st. The company reported $0.51 earnings per share for the quarter, beating the consensus estimate of $0.14 by $0.37. Omnicell had a negative net margin of 1.92% and a positive return on equity of 2.52%. The firm had revenue of $276.80 million during the quarter, compared to analyst estimates of $254.41 million. During the same quarter in the previous year, the firm earned $0.29 earnings per share. The firm’s revenue for the quarter was down 7.4% compared to the same quarter last year.

Institutional Trading of Omnicell

Several institutional investors and hedge funds have recently added to or reduced their stakes in OMCL. Nisa Investment Advisors LLC lifted its position in shares of Omnicell by 248.8% during the 2nd quarter. Nisa Investment Advisors LLC now owns 1,402 shares of the company’s stock valued at $38,000 after acquiring an additional 1,000 shares during the last quarter. EntryPoint Capital LLC raised its position in shares of Omnicell by 121.2% during the first quarter. EntryPoint Capital LLC now owns 2,455 shares of the company’s stock worth $72,000 after purchasing an additional 1,345 shares during the period. CWM LLC lifted its holdings in shares of Omnicell by 68.2% during the second quarter. CWM LLC now owns 3,048 shares of the company’s stock valued at $83,000 after purchasing an additional 1,236 shares during the last quarter. Benjamin Edwards Inc. boosted its position in shares of Omnicell by 36.4% in the 1st quarter. Benjamin Edwards Inc. now owns 3,253 shares of the company’s stock valued at $95,000 after purchasing an additional 868 shares during the period. Finally, Headlands Technologies LLC purchased a new position in Omnicell in the 2nd quarter worth about $104,000. 97.70% of the stock is owned by institutional investors and hedge funds.

Omnicell Company Profile

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.